Eli Lilly and Company (LLY)
NYSE: LLY · Real-Time Price · USD
760.13
-4.58 (-0.60%)
At close: Sep 17, 2025, 4:00 PM EDT
760.20
+0.07 (0.01%)
After-hours: Sep 17, 2025, 6:00 PM EDT
Eli Lilly Revenue
Eli Lilly had revenue of $15.56B in the quarter ending June 30, 2025, with 37.64% growth. This brings the company's revenue in the last twelve months to $53.26B, up 36.83% year-over-year. In the year 2024, Eli Lilly had annual revenue of $45.04B with 32.00% growth.
Revenue (ttm)
$53.26B
Revenue Growth
+36.83%
P/S Ratio
12.91
Revenue / Employee
$1,133,151
Employees
47,000
Market Cap
682.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
| Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
| Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
| Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
| Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
LLY News
- 3 hours ago - Eli Lilly: New Orforglipron Data In Focus As Commercial Business Outperforms - Seeking Alpha
- 7 hours ago - Data on Eli Lilly's Weight Loss Pill Hasn't Thrilled Investors. New Updates Are Complicating the Picture. - Barrons
- 7 hours ago - Eli Lilly's New Diabetes Drug Shows Better Blood Sugar, Weight Loss Results Than Rival - WSJ
- 8 hours ago - GLP-1 drugs could save millions of lives — and spark a pension crisis - Market Watch
- 9 hours ago - Lilly says its experimental GLP-1 pill better than Novo's Rybelsus in diabetes study - Reuters
- 9 hours ago - Eli Lilly's obesity pill outperforms Novo Nordisk's oral drug in head-to-head diabetes trial - CNBC
- 9 hours ago - Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial - PRNewsWire
- 12 hours ago - Lilly sees obesity drug leadership beyond US as it leans on consumer-focused strategy - Reuters